GeNO is a biopharmaceutical company focused on the design, development and commercialization of next-generation products to address unmet medical needs of patients with a variety of pulmonary and cardiac diseases. We are currently developing inhaled nitric oxide (NO) products for use in both the hospital setting and for longer-term applications outside of the hospital setting. These products, which are based on our GeNOsyl® drug delivery technology, are comprised of a single-use drug cassette and either a portable console or wearable controller. Our technology is designed to deliver NO safely for a variety of therapeutic indications and to provide clinicians with a solution that is more user-friendly than currently available NO delivery systems.

We are developing the GeNOsyl Acute DS to deliver a constant intra-breath concentration of therapeutic NO to patients who are on a ventilator in the hospital setting under close medical supervision. It can also be used with a nasal cannula or face mask. GeNOsyl Acute DS is comprised of a portable console and our single-use drug cassette. GeNOsyl Acute DS is designed to be simple and intuitive to use.

GeNO was founded when Dr. David Fine, with a 40 year background in NO and NO2 chemistry, recognized that, given the non-linear kinetics of the reaction of nitric oxide with oxygen, conventional methodology for delivering inhalable nitric oxide by dilution of concentrated nitric oxide would inevitably lead to the co-delivery of significant amounts of NO2. GeNO’s chemistry minimizes the nitric oxide dilution step and instead starts with NO2, chemically removes one of the oxygen atoms, and generates nitric oxide rapidly and quantitatively.

GeNO has two Investigational New Drug Applications (INDs) using its nitric oxide delivery system. The first clinical study uses NO as a diagnostic agent for administration as an adjunct for right heart catheterization in patients with Pulmonary Arterial Hypertension (WHO Group 1) to add information to improve clinical decision making. The second study is for the treatment of Pulmonary Hypertension in patients with Pulmonary Arterial Hypertension (PAH) and in patients with Pulmonary Hypertension secondary to Idiopathic Pulmonary Fibrosis (PH-IPF). Phase II development programs for both of these indications are ongoing.